Cagrilintide,
on the record.
Amylin analog·Tracking
Long-acting amylin analog under investigation, often paired with semaglutide as CagriSema in trials.
Not yet available. Cagrilintide is in active clinical study. We track every trial, paper, and FDA filing. When it crosses into prescribable, you'll know first.
01
The evidence.
0 PubMed
9 ClinicalTrials.gov
0 openFDA
ClinicalTrials.gov·May 22, 2026
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
Novo Nordisk A/S
ClinicalTrials.gov·May 19, 2026
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Novo Nordisk A/S
ClinicalTrials.gov·May 19, 2026
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk A/S
ClinicalTrials.gov·May 19, 2026
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
Novo Nordisk A/S
ClinicalTrials.gov·May 15, 2026
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
Novo Nordisk A/S
ClinicalTrials.gov·May 7, 2026
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Novo Nordisk A/S
ClinicalTrials.gov·May 5, 2026
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
ClinicalTrials.gov·May 5, 2026
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
ClinicalTrials.gov·May 5, 2026
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk A/S
CagrilintideAmylin analog
Notify me